Although the precise pathogenesis of POCD is still unclear, several investigations have verified that inflammatory cytokines-related mechanisms are involved in critical roles in the development and regression of POCD[8–9, 19]. As immune effector cells intrinsic to the central nervous system, microglia are known to mediate CNS inflammation mediated[20]. IBA-1 was used to label microglia in the murine hippocampus, and compared with the M group, microglial activation in the hippocampal tissues of the Z and J groups was substantially suppressed on post-operative day 3 (P < 0.05). Inflammatory factors may stimulate iNOS expression and release large amounts of NO. High concentrations of NO are cytotoxic, directly damaging DNA and mitochondrial function and impairing cells[21–22]. We detected iNOS expression in the hippocampus of groups C, D, M, Z, and J. Compared with group C iNOS in hippocampus of group M was significantly increased (P < 0.05), while EW formulation and basic formulation significantly inhibited the expression of iNOS. Lipopolysaccharide is a primary element of Gram-negative micro bacteria’s cell wall and binds specifically to TLR4, which can stimulate the NF-κB and produce inflammation in the central nervous system. At the same time, lipopolysaccharide can disrupt the blood-brain barrier and cause memory impairment[23]. Several studies have confirmed that lipopolysaccharide causes a peak in inflammation 6 hours after it enters the body[24], while the peak of POCD in mice after surgical stress is usually observed on the third day after surgery[25]. In this experiment, we found the inflammatory factor expressions in each group’s serum. Compared with 6 hours post-operation, no statistically significant differences were shown in IL-1β and IL-6 expressions in group M on a post-operative day 3 (P > 0.05) but IL-1β, IL-6, and TNF-α expressions in groups Z and J decreased on a post-operative day 3 (P < 0.05), suggesting that the EW formulation and basic formulation may improve the POCD development in mice by suppressing inflammatory responses in vivo.
EW has anti-inflammatory, antioxidant, and free radical scavenging properties[26]. Ten drugs from EW formulation (Margarita, Glycyrrhizae radix et rhizoma, Inulae radix, Aucklandiae radix, Aquilariae lignum resinatum, Bovis calculus artifactus, Piperis longi fructus, Euphorbiae humifusae hreba, Powerdered buffalo horn extract, and Moschus) were selected to form the EW basic formulation. Analysis of the Morris water maze data indicated that compared with the M group, the murine behavioral results in the Z and J groups were substantially improved (P < 0.05). By contrast, no statistically significant differences were detected between the J and Z groups (P > 0.05). Compared with group Z, no statistically significant differences were shown in IL-1β, TNF-α and IL-6 expressions at 6 hours post-operation in group J (P > 0.05), but microglial activation was decreased (P < 0.05). On post-operative day 3, IL-1β, TNF-α, IL-6 expressions, and microglial activation up-regulated in the J group (P < 0.05), suggesting that the basic formulation of EW can improve POCD in mice but the specific mechanism and effective ingredients of EW formulation in improving POCD still need to be further investigated.
Currently, no specific drugs for treating POCD are identified. Dexmedetomidine is currently recognized as an ameliorating agent for POCD[27]. In this experiment, no statistically significant differences were detected in behavioral test results between groups D, Z, and J (P > 0.05); compared with group D, group Z had decreased IL-1β, TNF-α and IL-6 expression levels at 6 hours and 3 days post-operation (P < 0.05). Compared with group D, IL-1 β, IL-6, and TNF-α expressions decreased in group J at 6 hours post-operation (P < 0.05) and TNF-α at 3 days post-operation (P < 0.05), but IL-6 and IL-1 β expressions at 3 days post-operation were not statistically significant (P > 0.05). Whether this is related to the time and duration of the administration still needs to be further investigated.
Western blotting and RT-qPCR data indicated that MyD88, NF-κB and TLR4 expression levels in the TZ and TJ groups on post-operative day 3 were reduced compared with the Z and J groups (P < 0.05), but behavioral tests showed no statistically significant differences (P > 0.05). Suggesting that the combination of EW and the TLR4 inhibitor TAK-242 did not enhance the POCD-improving effect of the EW formulation and the basic formulation, and that it may be associated with improvement in cognitive impairment due to multi-targeting with EW.
There are limitations to this experiment: the ten drugs that comprise the basic EW formulation are effective in treating nervous system disorders. For the rigor of the experiment, the drug composition of the formulations must be analyzed to accurately determine the active ingredients related to the nervous system. This is an area to be restored in the later stages of this study.
EW, one of the treasures in the history of Mongolian medicine, can improve not only POCD in mice but also neuronal behavioral performance in a rat injury model with middle artery occlusion-reperfusion by inhibiting neuronal apoptosis, promoting neurotransmitter transmission and repairing neuronal damage. Therefore, in addition to its simple anti-inflammatory effects, other mechanisms of EW in improving post-operative cognitive dysfunction may be worth further investigation.